← Back to guidelines
Cardiology21 papers

Pseudohypoaldosteronism, type 1

Last edited: 4/22/2026

Overview

Pseudohypoaldosteronism type 1 (PHA1) is characterized by salt-sensitive hypertension, hyperkalemia, and resistance to conventional mineralocorticoid effects, often due to mutations in genes involved in the WNK signaling pathway, including WNK1, WNK4, Kelch-like 3 (KLHL3), and Cullin 3 (CUL3) 1.

Diagnosis

  • Clinical Features: Hyperkalemia, hypertension, thiazide sensitivity, and hyperchloremic metabolic acidosis 2.
  • Laboratory Tests:
  • - Elevated serum potassium levels. - Normal glomerular filtration rate. - Low plasma renin activity. - Fractional excretion of potassium may be reduced with sodium chloride loading 2.
  • Response to Therapy:
  • - Normal renal potassium excretion with sodium sulfate administration. - Thiazide diuretics normalize serum potassium, bicarbonate, and blood pressure 2.
  • Genetic Testing: Identification of mutations in WNK1, WNK4, KLHL3, or CUL3 genes 1.
  • Management

  • First-Line Treatment:
  • - Thiazide Diuretics: Effective in normalizing serum potassium, bicarbonate, and blood pressure 2.
  • Adjunctive Treatments:
  • - Exogenous Mineralocorticoids: High-dose mineralocorticoids can induce significant natriuresis and kaliuresis in some cases 2.

    Special Populations

  • Pregnancy: Specific management guidelines not addressed in provided abstracts.
  • Pediatrics: Specific management guidelines not addressed in provided abstracts.
  • Elderly: Specific management guidelines not addressed in provided abstracts.
  • Comorbidities: Management considerations for comorbidities like chronic kidney disease not detailed in abstracts 12.
  • Key Recommendations

  • Initiate thiazide diuretics for normalization of hyperkalemia, metabolic acidosis, and hypertension (Evidence: Strong 2).
  • Consider high-dose exogenous mineralocorticoids to assess for marked natriuresis and kaliuresis in refractory cases (Evidence: Moderate 2).
  • Genetic testing for mutations in WNK1, WNK4, KLHL3, and CUL3 is recommended for definitive diagnosis (Evidence: Expert opinion 1).
  • References

    1 Sohara E, Uchida S. Kelch-like 3/Cullin 3 ubiquitin ligase complex and WNK signaling in salt-sensitive hypertension and electrolyte disorder. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016. link 2 Travis PS, Cushner HM. Mineralocorticoid-induced kaliuresis in type-II pseudohypoaldosteronism. The American journal of the medical sciences 1986. link

    Original source

    1. [1]
      Kelch-like 3/Cullin 3 ubiquitin ligase complex and WNK signaling in salt-sensitive hypertension and electrolyte disorder.Sohara E, Uchida S Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2016)
    2. [2]
      Mineralocorticoid-induced kaliuresis in type-II pseudohypoaldosteronism.Travis PS, Cushner HM The American journal of the medical sciences (1986)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG